Latest From Biotech Now

Patient and Venture Philanthropy Groups Presenting at 2014 BIO Investor Forum

BIF_logo

BIO’s alliance development team works to foster collaboration between the biotech industry and nonprofit disease foundations. In recent years, many nonprofit foundations have become more engaged in the drug development process – whether they have created clinical trial recruitment tools, established a disease registry, or funded emerging biotech companies. Recognizing the value of these initiatives to expedite research and drug development, BIO provides opportunities for venture philanthropies and patient organizations to connect with BIO members Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Corporate Venture Capital Company Profiles

cvc

To celebrate BIO Investor Forum, and, of course, Halloween, the Partnering Team over at BIO put together a succinct and definitive guide to the SCARY biopharma-related corporate venture capitalists (CVCs). Join us at BIO Investor Forum for the opportunity to have private 30-minute meetings with almost all the CVCs in our guide! Now, some SPOOKY facts about modern-day CVCs, based on publicly available information: CVCs prefer to be minority investors (generally contributing less than 20%). Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Hill: In War on Cancer, Patients at Risk of Becoming Commoditized

Ted Okon Photo copy

Ted Okon, executive director of the Community Oncology Alliance, highlights the significant progress the medical community has made in the war on cancer but stresses the importance of access to care to improve and lengthen patients’ lives. “More Americans with cancer face longer life expectancies as a result of increased awareness among at-risk populations, better preventative care, early screenings, and new therapies,” writes Okon. “However, despite significant progress in the war on cancer, unnecessary access Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Urges Comprehensive Tax Reform

72263479

Earlier this week, the Treasury Department issued a notice of its intent to propose rules to limit corporate inversions. In response, we are urging Congress and the Administration to reform the corporate tax system in order to maintain America’s global competitiveness, sustain and create American jobs, and encourage investments in the United States. The U.S. has one of the highest effective corporate tax rates in the world. Current U.S. corporate tax laws, including the lack Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,